Sandbox:therapy

• Asymptomatic patients with chronic lymphocytic leukemia are managed with observation, whereas symptomatic patients with chronic lymphocytic leukemia are treated with immunochemotherapy.

• Indications to initiate immunochemotherapy among patients with chronic lymphocytic leukemia include:

• Symptomatic chronic lymphocytic leukemia patients presenting with:

• Fever of unknown origin (>38.1°C for more than two weeks)
• Night sweats for more than one month
• Unintentional significant weight loss over a period of six months

• Patients presenting with thrombocytopenia or anemia due to bone marrow failure
• Patients presenting with refractory autoimmune anemia or refractory autoimmune thrombocytopenia
• Evidence of symptomatic splenomegaly, with the spleen being palpated more than 6cm below the costal margin
• Evidence of symptomatic progressive lymph nodes swelling, with a size greater than 10 cm in diameter
• Evidence of progressive and rapid lymphocytosis, which may be indicated by:

• An increase of greater than 50% over a 2-month period
• A lymphocyte doubling period shorter than six months

• The optimal therapy for chronic lymphocytic leukemia depends on a number of factors which include:

• The clinical presentation of the patients
• The stage of the tumor
• The presence of specific genetic mutations
• The performance status of the patients
• First line therapy vs. second line therapy

• The mainstay of therapy for asymptomatic chronic lymphocytic leukemia patients is immunochemotherapy.
• Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].